IP Library Granted Patent US 11,246,923
Granted Patent B2
US 11,246,923 · App. 15/886,918 · Granted Feb 15, 2022

Process for producing an allergen extract

Inventor: Jeronimo Carnes Sanchez (Madrid, ES)
Assignee: Laboratorios Leti, S.L. Unipersonal
A61K39/35C07K14/37C07K14/415C07K14/435C07K14/43531C07K14/47A61K2039/577
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,246,923
App. No.
15/886,918
Granted
Feb 15, 2022
Kind
B2
Abstract

The present invention discloses processes for producing native, depigmented and polymerised allergen extracts. The invention further discloses extracts produced via the processes, and pharmaceutical and vaccine compositions comprising the extracts, for diagnosis and treatment of allergy.

Claims (15)

1. A process for producing an allergen extract comprising:

a) contacting a source material comprising allergens with a lipid liquid extraction agent to produce a mixture containing lipids dissolved in a liquid phase and a solid phase consisting of source material residue comprising allergens and proteins, wherein the source material is selected from the group consisting of food allergens, peanuts, whole peanuts, air-borne allergens, pollen, tree pollen, weed pollen, grass pollen, cereal pollen, dust mites, fungi, moulds, mites, grasses, tree and weed allergens, epithelial allergens, animal hair, animal dander, cat hair, cat dander, dog hair, dog dander, insect allergens, cockroach allergens, flea allergens, bee venom and wasp venom,

b) subjecting the mixture to a first separation step to isolate the source material residue,

c) contacting the source material residue with an allergen extract agent to produce a mixture of allergens dissolved in a liquid phase, and a solid phase consisting of non-allergenic residue, wherein the allergen extract agent is an aqueous solution,

d) subjecting the mixture to a second separation step to isolate the allergens dissolved in the liquid phase, to produce a crude allergen extract,

e) subjecting the crude allergen extract to a first low molecular fraction removal step to remove molecules having a molecular size of less than 3.5 kDa, and

f) carrying out step e) until the crude allergen extract has a conductivity of below 1000 μS/cm at 3-5° C. to obtain a purified native allergen extract, the process comprising a further treatment step, comprising:

g) acidifying the purified native allergen extract to pH 2.0 to 4.0 thereby to produce an acidified extract and maintaining the acidified extract for 5-30 minutes, followed by subjecting the acidified extract to a second low molecular fraction removal step to remove molecules having a molecular size of less than 3.5 kDa, and adjusting the pH to 7.0-8.0 to produce a depigmented allergen extract.

2. The process as claimed in claim 1 wherein the low molecular fraction removal step is continued until the conductivity is less than 500 μS/cm at 3-5° C.

3. The process as claimed in claim 1 wherein the purified native allergen extract is acidified to pH 2.0 to 2.1.

4. The process as claimed in claim 1 wherein the purified native allergen extract is acidified to pH 2.0 to 3.0.

5. The process as claimed in claim 4 , further comprising a polymerisation step, comprising:

h) contacting the depigmented allergen extract with glutaraldehyde or formaldehyde thereby to produce a crude depigmented polymerised allergen extract,

i) subjecting the crude depigmented polymerised allergen extract to a molecular fraction removal step to remove molecules having a molecular size of less than 100 kDa, and

j) carrying out step i) until the crude depigmented polymerised allergen extract has a conductivity of below 210 μS/cm at 3-5° C. and/or is absent of glutaraldehyde as determined by UV or visible scanning, to obtain a depigmented polymerised allergen extract.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 058770 FRAME: 0916. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 2, 2022
From: LABORATORIOS LETI S.L.
To: LETI PHARMA, S.L
Reel/Frame 058950/0537 →
CHANGE OF NAME Recorded Jan 19, 2022
From: LABORATORIOS LETI, S.L.
To: LETI PHARMA, S.L.U.
Reel/Frame 058770/0916 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 044811 FRAME 0526. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 10, 2018
From: CARNES-SANCHEZ, JERONIMO
To: LABORATORIOS LETI, S.L. UNIPERSONAL
Reel/Frame 046113/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2018
From: CARNES-SANCHEZ, JERONIMO
To: LABORATORIOS LETI, S.L.
Reel/Frame 044811/0526 →
Priority Claims (1)
ES ES201030199 · Feb 12, 2010 · national
Continuity (2)
Continuation 13577787
Related Publication 20180200363A1 · Jul 19, 2018